Physician profile
Lina Chan
NPI 1659358042
$1,708.18
in general payments reported to CMS, 2019-2025
24 companies · $637 in 2025
The $637 reported for 2025 was more than what 83% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $202 · 2020: $143 · 2021: $165 · 2022: $279 · 2023: $128 · 2024: $153 · 2025: $637.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $919.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $918.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biotissue Holdings INC. | $240.97 | 2019-2023 | |
| Glaukos Corporation | $215.35 | 2025 | Photrexa Viscous and Photrexa, Idosetr, Kxl System (Not Refurbished) |
| Sun Pharmaceutical Industries INC. | $164.58 | 2020-2025 | |
| Novartis Pharmaceuticals Corporation | $140.55 | 2021-2023 | |
| Kedrion Biopharma, INC. | $117.83 | 2025 | Ryplazim |
| Bausch & Lomb Americas INC. | $112.63 | 2022-2025 | Miebo, Xiidra |
| Amgen INC. | $90.60 | 2024-2025 | Tepezza |
| Harrow Eye, LLC | $65.38 | 2025 | Vevye |
| Aerie Pharmaceuticals, INC. | $64.48 | 2019-2020 | |
| Dompe US, INC. | $61.20 | 2019-2021 | |
| Mallinckrodt Hospital Products INC. | $59.81 | 2020-2025 | Acthar |
| Johnson & Johnson Vision Care, INC. | $53.46 | 2023-2025 | Acuvue |
| Oyster Point Pharma, INC. | $50.16 | 2022-2023 | Tyrvaya |
| Rxsight INC | $42.74 | 2024-2025 | Rxsight Light Delivery Device (Ldd), Rxsight Contact Lens, Light Adjustable Lens (Lal) |
| Ani Pharmaceuticals, INC. | $39.78 | 2024-2025 | Purified Cortrophin Gel |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb, A Division of Bausch Health US, LLC | $24.74 | 2019 | |
| Johnson & Johnson Surgical Vision, INC. | $24.58 | 2019 | |
| Beaver-Visitec International, INC. | $23.83 | 2021 | |
| Eyevance Pharmaceuticals LLC | $21.92 | 2020 | |
| Shire North American Group INC | $21.70 | 2019 | |
| Alcon Vision LLC | $21.39 | 2022 | |
| Thea Pharma INC. | $18.33 | 2025 | Iyuzeh |
| Kala Pharmaceuticals, INC. | $16.99 | 2021 | |
| Abbvie INC. | $15.18 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lina Chan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.